Bacitracin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Bacitracin: From Topical Antibacterial Use to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Bacitracin is a polypeptide antibiotic marketed in the US as a topical ointment. The TxGNN model predicts it may be effective for punctate epithelial keratoconjunctivitis, but 0 clinical trials and 0 publications currently support this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 99.999% (rank 64 overall) |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
The licence records contain no approved-indication text, so the original labelled indication could not be extracted. The original use above is inferred from the product type (an ointment).
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available from DrugBank. Bacitracin is known to inhibit bacterial cell-wall synthesis by blocking dephosphorylation of C55-isoprenyl pyrophosphate. It acts mainly against gram-positive organisms, which is why it is used topically.
The link to the new indication is weak. Punctate epithelial keratoconjunctivitis is often viral, toxic, or dry-eye related rather than bacterial, so an antibacterial has no clear target. The TxGNN score of about 0.99999 should not be over-read. The top-ranked candidates all score almost identically, so the score does not discriminate between them. It probably reflects proximity in the knowledge graph rather than a real therapeutic signal.
The ophthalmic route is also unconfirmed. Route compatibility is still pending, and the only dosage form in the US records is an ointment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The 5 main entries below are the main listings out of 20. The records give no approved-indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| M004 | Bacitracin | Ointment | A-S Medication Solutions |
| M004 | Bacitracin | Ointment | BluePoint Laboratories |
| M004 | Bacitracin | Ointment | Rugby Laboratories |
| M004 | Bacitracin | Ointment | CVS Pharmacy |
| M004 | Bacitracin | Ointment | H E B |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature (L5). The mechanistic link is weak, because an antibacterial has little reason to help a largely non-bacterial condition. Safety data are also missing, which blocks any safety screening.
To proceed, the following is needed:
- The package insert warnings and contraindications, which are currently a blocking gap
- DrugBank mechanism of action data
- The labelled indications, so it is clear what counts as new use
- A check of whether an ophthalmic formulation exists or is feasible
- Evidence that bacterial infection contributes to this condition, plus any trials or literature testing bacitracin
Among the other top-ranked predictions, otitis externa (rank 4) is the only one with any literature. That includes one double-blind study of 151 patients using a polymyxin B plus bacitracin ointment. It is graded L4 and marked “Research Question”, and it may be a better lead than the current top prediction.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.